Unknown

Dataset Information

0

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D.


ABSTRACT: The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. To investigate the effects of tiotropium (Tio) and/or budesonide/formoterol (Bud/Form) on systemic inflammation biomarkers in stable COPD patients of group D, a randomized, open-label clinical trial was conducted.Eligible participants (n = 324) were randomized and received either Tio 18ug once daily (group I), Bud/Form 160/4.5ug twice daily (group II), Bud/Form 320/9ug twice daily (group III), or Tio 18ug once daily with Bud/Form 160/4.5ug twice daily (group IV) for 6 months. Systemic inflammation biomarkers were measured before randomization and during the treatment, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), serum amyloid A (SAA), tumor necrosis factor-? (TNF-?), fibrinogen (Fib), and white blood cell (WBC).After 6-month treatment, CRP levels in group II, group III and group IV changed by a median (interquartile range) of -1.25 (-3.29, 1.18) mg/L, -1.13 (-2.55, 0.77) mg/L, and -1.56 (-4.64, 0.22) mg/L respectively, all of which with statistical differences compared with group I. In addition, there were no treatment differences in terms of IL-8, SAA, TNF-?, Fib and WBC levels.A long-term treatment with Bud/Form alone or together with Tio can attenuate circulating CRP levels in COPD patients of group D, compared with Tio alone.

SUBMITTER: Lin YH 

PROVIDER: S-EPMC5568104 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D.

Lin Yi-Hua YH   Liao Xi-Ning XN   Fan Li-Li LL   Qu Yue-Jin YJ   Cheng De-Yun DY   Shi Yong-Hong YH  

PloS one 20170823 8


<h4>Background</h4>The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. To investigate the effects of tiotropium (Tio) and/or budesonide/formoterol (Bud/Form) on systemic inflammation biomarkers in stable COPD patients of group D, a randomized, open-label clinical trial was conducted.<h4>Methods</h4>Eligible participants (n = 324) were randomized and received either Tio 18ug once daily (group I), Bud/Form 160/4.5ug  ...[more]

Similar Datasets

| S-EPMC7924571 | biostudies-literature
| S-EPMC6224753 | biostudies-literature
| S-EPMC8496011 | biostudies-literature
| S-EPMC7708267 | biostudies-literature
| S-EPMC6595664 | biostudies-literature
| S-EPMC8384783 | biostudies-literature
| S-EPMC7939512 | biostudies-literature
| S-EPMC6824392 | biostudies-literature
| S-EPMC3425335 | biostudies-literature
| S-EPMC4409772 | biostudies-literature